Japanese Prime Minister Fumio Kishida recently announced that the country may consider authorizing Shionogi’s (TYO:4507) S-217622 coronavirus-3C-like-proteinase inhibitor based on strong data from a Phase 2a study. In that study, recipients of S-217622 had significant improvement in viral load reduction compared to those who received a placebo. In addition, those who received the experimental drug were 80% less likely to shed virus after four days.
Shionogi may file for approval as early as next week, according to Mainichi Japan.
Shionogi is gearing up for a Phase 3 study of S-217622.
If the company receives early authorization, it could provide enough of the drug candidate to meet the needs of one million people by the end of March.
The company’s stock ticked up almost 3% to ¥7,984.00.
Filed Under: Infectious Disease